Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
OROrganogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO)

NASDAQ Capital Market · Currency in USD
$0.99 ▼ -0.04 (-3.57%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.01 ▲ +0.02 (+1.69%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$1.03
Open
$1.02
Day's Range
$0.93 – $1.03
52 Week Range
$0.93 – $7.08
Volume
1,338,802
Avg. Volume
797,786
Market Cap
$127.80M
Beta (5Y Monthly)
1.27
PE Ratio (TTM)
--
EPS (TTM)
-$0.70
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$2.50

Profile: Organogenesis Holdings Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
854
CEO
Gary S. Gillheeney

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.18 · Revenue est. $52.10M
DateEst.Actual
Aug 6, 2026-$0.35-$0.71Miss
May 7, 2026-$0.29-$0.37Miss
Feb 26, 2026$0.22$0.31Beat
Nov 6, 2025$0.21$0.18Miss
Aug 7, 2025$0.07-$0.09Miss
May 8, 2025$0.04-$0.13Miss

Analyst view

Consensus price target
$2.50 ▲ +151.7%
Range $2.00 – $3.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on ORGO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.